US Patent 10060921 Methods of treating transthyretin (TTR) mediated amyloidosis
Patent 10060921 was granted and assigned to Alnylam Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 31 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+252 characters)
Article
Patent abstract
Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
Edits on 26 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100609210
Date of Patent
August 28, 2018
0Patent Application Number
155076910
Date Filed
August 27, 2015
0Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100609210
Date of Patent
August 28, 2018
0Patent Application Number
155076910
Date Filed
August 27, 2015
0Patent Primary Examiner
Edits on 21 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10060921 Methods of treating transthyretin (TTR) mediated amyloidosis
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10060921
Date of patent
August 28, 2018
Patent application number
15507691
Date Filed
August 27, 2015
Patent primary examiner
Find more entities like US Patent 10060921 Methods of treating transthyretin (TTR) mediated amyloidosis
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
